Subscribe
19 May 2017Americas

AbbVie Humira patent invalidated by PTAB

AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira (adalimumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
AbbVie and Alvotech settle all US Humira litigation
10 March 2022   AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).
Big Pharma
Got a patent, now where to validate?
22 March 2021   For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Generics
AbbVie and Alvotech settle all US Humira litigation
10 March 2022   AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).
Big Pharma
Got a patent, now where to validate?
22 March 2021   For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.

More on this story

Generics
AbbVie and Alvotech settle all US Humira litigation
10 March 2022   AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).
Big Pharma
Got a patent, now where to validate?
22 March 2021   For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.

More features

The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
The right formula: Minimising the cost of chemical and pharma patents
‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm